Previous 10 | Next 10 |
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022, before markets open. Aurinia’s management team will host a ...
Do you like stocks with triple-digit revenue growth? Here are three companies you might want to dig into. First up is Outset Medical (NASDAQ: OM) , a healthcare company that doubled its sales last year. The next one is Aurinia Pharmaceuticals (NASDAQ: AUPH) ; analysts ar...
The shares of Canadian biotech Aurinia Pharmaceuticals (NASDAQ:AUPH) are trading lower in the morning hours Thursday after RBC Capital Markets lowered its price target, citing Omicron-driven impact for sales of the company’s lupus nephritis therapy, Lupkynis. Ahead of Aurinia’s ...
– Company seeks proposals to create and sustain community-focused programs to support underserved populations with these conditions – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals livi...
Presentations include new analyses of AURORA 1 and details on the ENLIGHT-LN registry Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today an...
The shares of the commercial-stage biopharmaceutical company Aurinia Pharmaceuticals (AUPH +10.6%) have added more than a tenth on Wednesday to record the biggest intraday gain in over three months amid rising chatter on social media. Currently, about 3.8 million Aurinia (NASDAQ:AUPH) shares ...
Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 2.8% on a report that a European-based investor group is campaigning for the biotech to begin a strategic review. Aurinia holders, led by Switzerland-based MKT Tactical Fund, has written to the AUPH chairman, asking that the board to hire a bank...
Aurinia Pharmaceuticals, along with biotechs in general, has been beaten down recently. I explore the reasons specific to Aurinia and then compare recent results to my valuation model. My model turns out to be very conservative and it still arrives at a target price of $75 for AUP...
The commercial-stage biotech, Aurinia Pharmaceuticals (AUPH -4.7%), is trading lower for the third straight session on Wednesday to reach a seven-month low after several Wall Street analysts trimmed their price targets on the stock citing the company’s lackluster Q4 2021 results. ...
Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...
2024-06-27 04:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four...